BCL-XL Inhibitor A-1155463: Potent, Selective Apoptosis Modulator for Cancer Research

Executive Summary: BCL-XL inhibitor A-1155463 is a highly potent and selective small molecule that binds BCL-XL with a Ki of 19 nM, disrupting its anti-apoptotic function in BCL-XL-dependent cancer cells (Koessinger et al., 2022). In preclinical models, A-1155463 induces robust apoptosis and inhibits tumor growth, particularly in hematological malignancies and solid tumors with high apoptotic priming (source). In vivo, dosing at 5 mg/kg in SCID-Beige mice results in transient platelet depletion, confirming on-target activity. A-1155463 offers superior selectivity and potency compared to earlier BCL-XL inhibitors, making it a tool of choice for dissecting apoptotic signaling pathways in cancer research (APExBIO). The compound is currently in preclinical development and is available from APExBIO for research use only.

Biological Rationale

BCL-XL is an anti-apoptotic member of the BCL-2 family, which regulates the intrinsic (mitochondrial) apoptotic pathway in mammalian cells (Koessinger et al., 2022). Overexpression of BCL-XL is observed in many hematological malignancies and solid tumors, contributing to drug resistance and tumor persistence (source). Targeting BCL-XL restores apoptotic sensitivity in cancer cells that are otherwise refractory to conventional therapies. Selective inhibition of BCL-XL is particularly relevant for tumors with high apoptotic priming, such as glioblastoma and certain lymphomas (source).

Mechanism of Action of BCL-XL inhibitor A-1155463

A-1155463 is a BH3-mimetic designed to selectively bind the hydrophobic groove of BCL-XL, blocking its interaction with pro-apoptotic proteins (APExBIO). This displacement relieves inhibition of pro-apoptotic BCL-2 family members (e.g., BAX, BAK), resulting in mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and downstream caspase activation (source). The high affinity (Ki = 19 nM) and selectivity for BCL-XL over other BCL-2 proteins distinguish A-1155463 from earlier inhibitors such as WEHI-539.

Evidence & Benchmarks

• A-1155463 binds BCL-XL with a Ki of 19 nM, showing high selectivity versus BCL-2 and MCL-1 (APExBIO).
• In vitro, A-1155463 is more potent than WEHI-539 in inducing apoptosis in BCL-XL-dependent cell lines (Peptone-Bacteriological).
• In vivo, 5 mg/kg intraperitoneal dosing in SCID-Beige mice causes transient platelet depletion, indicating on-target BCL-XL inhibition (Koessinger et al., 2022).
• Fourteen days of daily dosing significantly inhibits tumor growth in BCL-XL-dependent H146 xenograft models; tumor growth resumes upon cessation (Koessinger et al., 2022).
• Compared to navitoclax (a dual BCL-2/BCL-XL inhibitor), A-1155463 demonstrates improved selectivity, minimizing off-target toxicity (Koessinger et al., 2022).
• BCL-XL inhibition restores apoptotic sensitivity in glioblastoma and other tumors with high BCL-XL expression (Koessinger et al., 2022).
• Preclinical development status: A-1155463 is not approved for clinical use; it is a research-only tool (APExBIO).

This article provides a comprehensive update compared to 'BCL-XL Inhibitor A-1155463: Advancing Apoptosis Induction...', by integrating recent in vivo benchmarks and clarifying storage and handling parameters for translational workflows. For a strategic overview, see 'Strategic Disruption of Apoptosis Resistance...'—this article extends that discussion by providing more granular, quantitative evidence. For a mechanistic deep dive, refer to 'Harnessing Selective BCL-XL Inhibition: Mechanistic Found...'; here, we focus on benchmark comparisons and translational parameters.

Applications, Limits & Misconceptions

A-1155463 is primarily used for dissecting apoptotic signaling in BCL-XL-dependent cancer models and for evaluating the efficacy of targeted apoptosis modulators in preclinical drug discovery. Its selectivity makes it valuable for combination studies, especially where resistance to conventional chemotherapies is mediated by BCL-XL overexpression. Applications include:

• Mechanistic studies of the BCL-2 family protein pathway in apoptosis induction.
• Screening for synthetic lethality or combinatorial efficacy with other targeted agents.
• Preclinical modeling of drug resistance in hematological malignancies and solid tumors.
• Evaluating on-target versus off-target toxicity profiles in animal models.

Common Pitfalls or Misconceptions

• A-1155463 is not a pan-BCL-2 inhibitor; it does not inhibit BCL-2 or MCL-1 at physiologically relevant concentrations.
• It is not suitable for clinical (human) administration; it is a research-use-only compound (APExBIO).
• Platelet toxicity is a predictable on-target effect due to BCL-XL dependence in mature platelets; users must control for hematological parameters in vivo.
• Solubility is excellent in DMSO (≥67 mg/mL) but negligible in water or ethanol; improper solubilization will affect experimental outcomes.
• Long-term solution storage is not recommended; stability is best maintained at -20°C and for short-term use only.

Workflow Integration & Parameters

A-1155463 (B6163) is supplied as a solid and should be stored at -20°C. For in vitro applications, dissolve at ≥67 mg/mL in DMSO; do not attempt dissolution in water or ethanol due to insolubility. For in vivo studies, vehicle selection and dosing regime should mimic preclinical benchmarks (e.g., 5 mg/kg intraperitoneally in SCID-Beige mice). Platelet counts should be monitored during in vivo studies to assess on-target effects.

Researchers are advised to review both the product datasheet (BCL-XL inhibitor A-1155463) and pertinent peer-reviewed literature to ensure optimal protocol design. For further context on apoptosis pathway mapping, see 'BCL-XL Inhibitor A-1155463: Unraveling Apoptotic Pathways...', which focuses on pathway-level analysis—this article complements that by detailing workflow and dosing specifics.

Conclusion & Outlook

BCL-XL inhibitor A-1155463 is a validated, selective tool for probing apoptotic signaling and overcoming drug resistance in BCL-XL-dependent hematological malignancies and solid tumors. Its high potency, selectivity, and robust in vivo activity distinguish it from earlier BH3-mimetics. As preclinical studies expand, A-1155463 will remain integral for evaluating next-generation combinations in oncology research (Koessinger et al., 2022). For reliable sourcing and technical documentation, APExBIO remains the primary provider (source).